Intuitive Surgical unveils real-time surgical insights on its da Vinci 5, enhancing precision, safety, and efficiency with advanced software features.
Intuitive Surgical stock (NASDAQ: ISRG) has dropped 16% this year, notably lagging behind the S&P 500's 10% increase. The stock has experienced downward pressure recently after management indicated that potential tariffs may adversely affect its performance in 2026.
Intuitive Surgical, Inc. (NASDAQ:ISRG ) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 9:30 AM EDT Company Participants David Rosa - CEO & Director Jamie Samath - CFO, Head of Business Technology & Enterprise Technology Leader Conference Call Participants Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Presentation Larry Biegelsen Senior Medical Device Equity Research Analyst All right. Good morning, everyone.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Intuitive Surgical, Inc. (ISRG) closed at $476.16 in the latest trading session, marking a +1.34% move from the prior day.
Investors have been looking at robotics companies for several decades. But artificial intelligence (AI) is taking robotics beyond basic automation by bringing more precision, flexibility, and adaptability into the sector.
Recently, Zacks.com users have been paying close attention to Intuitive Surgical (ISRG). This makes it worthwhile to examine what the stock has in store.
Intuitive Surgical expands Ion into Australia and Korea after 52% procedure growth, testing Asia-Pacific adoption despite budget headwinds.
Intuitive Surgical's Ion platform saw Q2 procedures jump 52% to 35,000, expanding globally as utilization rises despite softer system placements.
Intuitive Surgical's da Vinci system is driving strong global growth, with 17% YoY procedure growth and expanding adoption across hospitals and specialties. Recurring revenue streams from system sales, procedures, and services support robust financials, including 21% YoY revenue growth and 68% gross margins. The company's expanding installed base and accelerating procedure growth position it for continued earnings stability and long-term shareholder returns.
Intuitive Surgical's Q2 revenues and procedure gains look good, but tariffs, cost inflation, and margin pressure spur a post-earnings selloff.
Intuitive Surgical (ISRG) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.